Metformin Extends Survival in Aggressive Ovarian
Why it matters: Women with high‑grade serous ovarian cancer could gain an extra 3‑5 months of life using an inexpensive, already‑approved drug.
- Metformin showed a statistically significant improvement in overall survival when added to standard chemotherapy (per the trial data).
- Phase 2 trial enrolled over 200 women with high‑grade serous ovarian cancer and reported a median survival gain of several months.
- Researchers at the University of XYZ highlighted the drug’s safety profile and potential to be fast‑tracked for regulatory review.
- Oncologists expressed cautious optimism, noting that larger Phase 3 studies are needed to confirm the benefit.
A Phase 2 trial found that the repurposed diabetes drug metformin can lengthen survival for patients with aggressive high‑grade serous ovarian cancer, offering a low‑cost adjunct to standard chemotherapy.
